This project is no longer accepting applications. Subscribe to our newsletter to be notified of new projects!
Exploring Gene Therapy and Genome Editing Technologies with a Focus on CRISPR-Cas9 Mechanism, Ethical Considerations, and Genotoxicity Studies
This project aims to explore key aspects of gene editing and gene therapy, focusing on current techniques, historical evolution, and the associated challenges. You will delve into the mechanisms and applications of gene editing technologies, understand how they have evolved from early experiments to sophisticated tools used in modern biotechnology and medicine. Utilizing bioinformatics tools, you will conduct an analysis to understand disease modalities, interpreting genomic data to identify and characterize structural variants, and assessing their potential impact on gene function and disease progression.
The project will also investigate genomic instability and off-target effects that can arise from gene editing, emphasizing their implications for therapeutic safety and efficacy. Additionally, you will explore the role of bioinformatics as a powerful tool for deciphering disease modalities, leveraging computational approaches to analyze genomic data and understand disease mechanisms at a molecular level.
Through this comprehensive exploration, this Build Project seeks to equip you with a deep understanding of the complexities and potentials of gene editing technologies in healthcare and biotechnology. You will produce a report about the evolution and current state of gene editing techniques, including a historical overview of gene therapy. It will also cover the mechanisms of genomic instability and off-target effects resulting from gene editing, providing insights into their implications for therapeutic safety and efficacy.
Get access to all of our Build projects, including this one, by creating your Build account!
Get started by submitting your application.
We'll notify you when projects reopen. In the meantime, you can explore our resources and learn more about our Fellows.